PHASE 1B/2 STUDY OF BXCL701, AN ORAL ACTIVATOR OF THE SYSTEMIC INNATE IMMUNITY PATHWAY, COMBINED WITH PEMBROLIZUMAB (PEMBRO), IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) Meeting Abstract

cited authors

  • Aggarwal, Rahul; Costin, Dan; Zhang, Jingsong; Monk, Paul; Linch, Mark; Karsh, Lawrence; Healey, Diane; Corsi-Travali, Stefani; Adurthi, Sreenivas; Adedoyin, Adedayo; O'Neill, Vincent

Publication Date

  • November 1, 2020

webpage

published in

category

start page

  • A208

end page

  • A209

volume

  • 8